Sweden-based Kancera has applied to the Swedish regulatory authorities to conduct a Phase II clinical trial of KAND567 in Covid-19.
Kancera has previously filed a patent for KAND567 as a treatment for hyperinflammation caused by viral infections and myocardial infarction. An over-reaction of the immune system, known as the cytokine storm, has been a major cause of death in patients with Covid-19, which is caused by the virus SARS-CoV-2.
KANDA567 blocks the Fractalkine receptor, which plays a key role in the immune system, and works selectively against cytokines involved in hyperinflammation in Covid-19. Therefore, the company believes its drug can support the immune system's ability to combat the viral pandemic disease.
The trial will be carried out in collaboration with the Capio St. Görans Hospital and the Science for Life Laboratory, Stockholm.